Nicox (NICXF)
(Delayed Data from OTC)
$0.44 USD
-0.20 (-30.84%)
Updated Dec 28, 2023 12:11 PM ET
4-Sell of 5 4
F Value D Growth NA Momentum NA VGM
Brokerage Reports
0 items in cart
Nicox SA [NICXF]
Reports for Purchase
Showing records 1 - 20 ( 119 total )
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Phase 3 Glaucoma Trial Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Debt Restructuring Extends Cash Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Licensing Agreement in Japan Extends Cash Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
VYZULTA Patent Eligible for Five-Year Extension; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Phase 3b Trial in Glaucoma Starts Patient Screening; Reiterate Buy; Lowering PT to 1
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Animal data show favourable profile vs Lumigan
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Q323 update confirms trajectory for NCX-470
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
1H23 Financial Results and 3Q23 Highlights Reported; Reiterate Buy; Lowering PT to 2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Denali trial remains on track for 2025 readout
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
2Q23 Financial Highlights Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Nicox provides NCX-470 sales potential estimates
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
NCX 470 Potential Global Sales Estimated to Exceed $300M; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
New Animal Data Presented at ARVO 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
1Q23 Financial Highlights Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Chinese partner Ocumension files Zerviate NDA
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
ZERVIATE New Drug Application Accepted in China; Reiterate Buy; Adjusting PT to 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Continuing NCX-470 development strategy
Provider: Edison Investment Research Limited
Analyst: HEMAMI P
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Nicox SA
Industry: Medical - Biomedical and Genetics
2022 Preliminary Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R